SASS 001
Alternative Names: SASS-001Latest Information Update: 05 Feb 2025
At a glance
- Originator Apnimed - Shionogi (JV)
- Class Analgesics; Aniline compounds; Antitussives; Chlorobenzenes; Propionic acids; Pyridines; Sleep disorder therapies; Small molecules; Triazines
- Mechanism of Action Purinergic P2X3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Sleep apnoea syndrome
Most Recent Events
- 29 Jan 2025 Phase-II clinical trials in Sleep apnoea syndrome in USA (PO) (NCT06776432)
- 21 Jan 2025 Early research in Sleep apnoea syndrome in USA (PO)
- 15 Jan 2025 Apnimed-Shionogi plans a phase II trial for Sleep apnoea syndrome (PO) in January 2025 (NCT06776432)